Sweden-based private equity fund EQT said it had made a cash offer for the remaining shares in Swedish biopharmaceuticals group Karo Pharma.
The total value of the offer is $215.15m, valuing Karo Pharma at $1.6bn, EQT subsidiary Karo Intressenter said in a statement.
EQT is a purpose-driven global investment organization with more than €70bn in assets under management, across 27 active funds. EQT has portfolio companies in Europe, Asia-Pacific and the Americas with total sales of approximately €29bn and more than 175,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.
Read more: Reuters
